- Home
- HIT vs CVKD Comparison
HIT vs CVKD Comparison
Compare HIT & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIT
- CVKD
- Stock Information
- Founded
- HIT 1964
- CVKD 2022
- Country
- HIT United States
- CVKD United States
- Employees
- HIT N/A
- CVKD N/A
- Industry
- HIT Specialty Insurers
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- HIT Finance
- CVKD Health Care
- Exchange
- HIT Nasdaq
- CVKD Nasdaq
- Market Cap
- HIT 37.2M
- CVKD 33.7M
- IPO Year
- HIT 2024
- CVKD 2023
- Fundamental
- Price
- HIT $0.63
- CVKD $15.10
- Analyst Decision
- HIT
- CVKD Strong Buy
- Analyst Count
- HIT 0
- CVKD 1
- Target Price
- HIT N/A
- CVKD $32.00
- AVG Volume (30 Days)
- HIT 607.7K
- CVKD 23.6K
- Earning Date
- HIT 04-14-2025
- CVKD 05-08-2025
- Dividend Yield
- HIT N/A
- CVKD N/A
- EPS Growth
- HIT N/A
- CVKD N/A
- EPS
- HIT 0.02
- CVKD N/A
- Revenue
- HIT $22,380,959.00
- CVKD N/A
- Revenue This Year
- HIT $58.79
- CVKD N/A
- Revenue Next Year
- HIT N/A
- CVKD N/A
- P/E Ratio
- HIT $34.43
- CVKD N/A
- Revenue Growth
- HIT 11.24
- CVKD N/A
- 52 Week Low
- HIT $0.51
- CVKD $5.70
- 52 Week High
- HIT $7.59
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- HIT N/A
- CVKD 50.87
- Support Level
- HIT N/A
- CVKD $13.00
- Resistance Level
- HIT N/A
- CVKD $15.87
- Average True Range (ATR)
- HIT 0.00
- CVKD 0.87
- MACD
- HIT 0.00
- CVKD 0.13
- Stochastic Oscillator
- HIT 0.00
- CVKD 72.41
About HIT Health In Tech Inc. Class A Common Stock
Health In Tech Inc is an insurance technology platform company. It offers a marketplace that processes in the healthcare industry through vertical integration, process simplification, and automation. The group removed friction and complexities, it streamlined the underwriting, sales, and service process for insurance companies, licensed brokers, and TPAs.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.